Voriconazole and squamous cell carcinoma after lung transplantation: A multicenter study

摘要: This study evaluated the independent contribution of voriconazole to development squamous cell carcinoma (SCC) in lung transplant recipients, by attempting account for important confounding factors, particularly immunosuppression. international, multicenter, retrospective, cohort included adult patients who underwent transplantation during 2005-2008. Cox regression analysis was used assess effects and other azoles, analyzed as time-dependent variables, on risk developing biopsy-confirmed SCC. Nine hundred recipients were included. Median follow-up time from end 3.51 years. In a model, exposure alone (adjusted hazard ratio 2.39, 95% confidence interval 1.31-4.37) azole(s) 3.45, 1.07-11.06) associated with SCC compared those unexposed after controlling confounders including immunosuppressants. Exposure increased skin recipients. Residual could not be ruled out because use proxy variables control some confounders. Benefits when prescribed recipients should carefully weighed versus potential EU PAS registration number: EUPAS5269.